Predictors of treatment outcomes with Auto-titrating CPAP therapy in adults with Obstructive Sleep Apnea

Olabimpe S Fashanu MD MPH¹, Stuart F Quan MD ^{1,2}

1. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2. Asthma and Airways Research Center, University of Arizona College of Medicine, Tucson, AZ, USA

Corresponding Author

Olabimpe S Fashanu

Division of Sleep and Circadian Disorders

231 Longwood Avenue

Boston MA 02115

ofashanu@bwh.harvard.edu

This study was conducted at the Brigham and Women's Hospital in Boston MA

All authors have seen and approved the manuscript

There was no financial support for any of the authors

Conflicts of Interest

Stuart F Quan is a consultant for Jazz Pharmaceuticals, Bryte Bed, Best Doctors and
Whispersom.

The other author has no conflicts of interest.

Abstract

Objectives: To determine factors that predict OSA therapy outcomes with auto-titrating positive airway pressure (APAP).

Methods: We sequentially grouped patients from a retrospective cohort based on APAP efficacy (sufficiently vs. insufficiently treated; insufficiently treatment defined as residual AHI of ≥ 5); therapy adherence (compliant vs. non-compliant, non-compliance defined as $< 70\%$ usage for ≥ 4 hours/night); and therapy outcomes (optimal vs non-optimal (non-optimal outcomes defined as non-compliant and insufficiently treated). We subsequently compared each group.

Results:

The insufficiently treated were older (68.4 ± 12.5 vs. 60.4 ± 13.1 years, $p < 0.01$) and had lower BMI (31.9 ± 6.3 vs. 37.9 ± 9.1 kg/m², $p < 0.01$). They had higher baseline central apnea indices (CAI), longer leaks, higher peak pressures and were less compliant.

The non-compliant were younger (61.1 ± 12.6 vs. 65.5 ± 13.2 years, $p = 0.03$) and comprised more females (56.1 vs. 43.9%, $p = 0.04$). The leak duration per usage hour was higher in the non-compliant (13.9 ± 42.1 vs. 1.83 ± 3.53 minutes/hour, $p < 0.01$). The non-optimally treated had lower BMI, longer leaks and shorter nightly usage.

Following multivariate analysis, the aforementioned variables except age were predictive of higher residual AHI, while age and gender predicted compliance.

Conclusions:

Various demographic and clinical factors were predictive of treatment efficacy and adherence.

Overall, lower BMI, longer leaks and shorter nightly usage predicted poor therapy outcomes.

Keywords: Auto-titrating Positive Airway Pressure, CPAP Compliance, CPAP Efficacy, Residual Apnea Hypopnea Index, Residual sleep apnea

Introduction:

Continuous positive airway pressure (CPAP) is the gold standard in the treatment of obstructive sleep apnea (OSA); obstructive events are virtually eliminated in compliant patients. Until recently, CPAP therapy was primarily delivered via the fixed pressure mode. However, auto-titrating positive airway pressure (APAP) during which airway pressures are automatically adjusted throughout the sleep period is also a recommended option [1] and has become an increasingly popular mode of CPAP delivery for the treatment of uncomplicated OSA.

CPAP treatment outcomes are often limited by poor treatment adherence. To achieve optimal patient outcomes, CPAP efficacy must be paired with adequate compliance with treatment.

Prior studies on positive airway pressure (PAP) outcomes have either been done using a variety of PAP delivery modes [2] or have not documented that the studies were limited to a particular mode of PAP delivery [3]. Although treatment efficacy with APAP is generally comparable to CPAP, with APAP the machine- specific algorithmic automatic adjustment in airway pressure may sometimes be inadequate to result in a sufficient reduction in the apnea hypopnea index (AHI) [4] [5]. The goal of this study was to determine demographic and clinical factors that may predict therapy outcomes with APAP in patients with OSA. Outcomes of

interest were treatment effectiveness as determined by a reduction in AHI and adherence. This knowledge is crucial to developing specific interventions targeted at achieving better treatment outcomes.

Methods:

Data were analyzed from a retrospective cohort of adult patients aged ≥ 18 years treated with APAP at the Brigham and Women's Faulkner Hospital Sleep Clinic between September 2015 and September 2018. As described previously [6], to be included in the study, patients were required to have been treated with APAP and not fixed pressure CPAP, and to have been followed up in the sleep clinic within 18 months of their CPAP titration polysomnogram. Patients who had comorbid sleep related breathing disorders including central sleep apnea, sleep related hypoxemia or hypoventilation were excluded. Of the 922 charts reviewed, a total of 189 patients initially fulfilled study criteria. However, for uniformity of analyses, only patients who were prescribed APAP devices manufactured by Philips Respironics, Murrysville, PA were included in this study. Therefore, 17 patients using other devices were excluded, resulting in a final cohort comprising 172 patients. Demographic, anthropometric and clinical data including 30-day APAP compliance data were extracted from the electronic medical record on eligible study participants. Therapy effectiveness was defined as residual AHI < 5 /h) and treatment adherence was defined as APAP device usage of $\geq 70\%$ of nights for at least 4 h/night over 30 consecutive nights.

Definition of Leaks: There is unfortunately no universal definition of significant unintentional mask leaks, and the definition varies between CPAP manufacturers. Large leaks are generally

considered significant when the machine manufacturer is concerned that the leak will impact the proper function of the machine. Philips Respironics APAP compliance data documented the duration of large leaks per day. The manufacturer defines small and large mask leaks as ≤ 1 and >1 hour of large leak per day respectively [7] . This definition may however, be impractical if not clinically correlated given individual variability in hours of usage of APAP. We adjusted the duration of large leaks per day for both hours of nightly usage and for pressure delivery using the pressure at which the APAP device spent 90% of the time at or below (90th percentile pressure).

Statistical Analysis:

Baseline characteristics of study participants were summarized as means and standard deviations for continuous and interval variables, and as percentages for categorical variables. To evaluate factors impacting therapy effectiveness, patients were divided into 2 groups based on whether their residual AHI was $\geq$ or < 5 /hour. Similarly, to assess treatment adherence, patients also were assigned into 2 groups based on whether they met the treatment adherence criteria. We then compared patients with optimal outcomes and those without optimal outcomes (compliant and sufficiently treated vs. non-compliant and insufficiently treated). Continuous variables were compared using Student's unpaired t test. Categorical variables were compared using the χ^2 test. Multivariate logistic regression analysis was conducted to assess the impact of relevant covariates on the observed differences in treatment outcomes with APAP. Statistical tests were performed using GNU PSPP 1.4.1 Free Software Foundation, Boston, MA. A p-value of ≤ 0.05 , two tailed was considered statistically significant.

Results:

Table 1 shows the baseline characteristics of the 172 study participants. They were majority male, middle to older aged, obese and generally had severe OSA; most were reported to have loud disruptive snoring. The majority of the cohort had comorbid hypertension, 30.2% had a history of depression and 25.0% had comorbid diabetes mellitus.

Treatment effectiveness and compliance data are displayed in Table 2. Overall, 37.8% of patients had residual AHI ≥ 5 on APAP therapy, with 40.2% of participants being non-compliant. They also had average mask leak durations of 6.7 ± 27.3 minutes of large leaks per hour suggesting that patients spent 11% to 45% of their time on APAP with large leaks.

Table 3 shows a comparison of clinical and anthropometric data as a function of whether APAP treatment was effective. The patients with insufficiently treated OSA on APAP (Residual AHI (RAHI) ≥ 5) were older (68.4 ± 12.5 vs. 60.4 ± 13.1 years, $p < 0.01$) and had lower body mass indices (31.9 ± 6.3 vs. 37.9 ± 9.1 kg/m², $p < 0.01$). They had slightly more central apneas at baseline (2.5 ± 4.2 vs 1.2 ± 3.6 events per hour, $p=0.046$), modestly higher peak PAP pressures (11.4 ± 2.6 vs 10.3 ± 2.4 , $p = 0.013$) and had much longer durations of mask leaks per hour of usage (14.1 ± 42.7 vs 2.1 ± 6.2 minutes per hour, $p < 0.01$). However, we did not find an association between mask types and higher residual AHI. There was however >50% missing data on mask types. They were also less compliant with APAP when comparing their 4-hour nightly usage (61.2 ± 33.6 vs $73.9 \pm 27.4\%$, $p < 0.01$). Following multivariate analyses, BMI (OR: 0.85, 95% CI: 0.77-0.93, $p < 0.01$), baseline central apnea index (OR: 1.11, 95% CI: 1.01-1.21, $p = 0.04$), leak duration (OR: 1.04, 95% CI: 1.02-1.06, $p < 0.01$), APAP compliance (OR: 0.98, 95%

CI:0.96 -0.99, $p=0.048$) and peak average pressure (OR: 1.29, 95% CI: 1.11-1.46, $p<0.01$) were associated with insufficiently treated OSA on APAP.

As shown in Table 4, the non-compliant group of patients were younger and comprised mostly females. There were few anthropometric and clinical differences between non-compliant and compliant patients. However, non-compliance was associated with longer leak durations (13.9 ± 42.1 vs. 1.8 ± 3.5 minutes per hour of usage, $p<0.01$). Although a higher percentage of non-compliant patients had comorbid depression, the difference only approached statistical significance. Furthermore, the presence of common cardiovascular comorbidities such as hypertension and diabetes mellitus was not associated with differences in compliance in our study. However, in multivariate modelling, only age (OR: 0.96, 95% CI:0.94-0.98, $p <0.01$) and possibly female gender (OR: 0.51, 95%CI -0.19-1.22, $p= 0.058$) were associated with APAP compliance.

Table 5 shows a comparison of patients who were optimally treated (compliant and adequately treated with APAP) and those who were not optimally treated (non-adherent and insufficiently treated with APAP). The non-optimally treated group had lower BMI (33.2 ± 7.8 vs 37.5 ± 8.3 kg/m², $p = 0.02$), higher leak duration per hour of usage (26.9 ± 60.8 vs 1.1 ± 2.2 minutes per hour, $p < 0.01$) and lower nightly usage (2.5 ± 1.4 vs 6.9 ± 1.7 hours, $p < 0.01$).

Discussion:

To our knowledge, this is the first study that has examined the two major factors predicting treatment outcomes (AHI reduction and compliance) in a cohort of patients exclusively treated with APAP. We found that several clinical, demographic and anthropometric

factors were associated with worse treatment effectiveness and compliance and that large air leaks were of particular importance.

Our study showed that 37.8% of study participants were insufficiently treated with APAP, evidenced by significant residual sleep apnea ($AHI \geq 5$ per hour). This is somewhat higher than has been reported in prior similar studies. One study reported 22.1% [3] and another 32.2% [8]. These differences in findings may be attributable to variations in patient demographics and study methods. For instance, the aforementioned studies had a younger population with average ages of 58.2 and 54.7 years respectively compared to our study which had an average age of 63.4 years. This is particularly relevant as one study examining data from the French national sleep database [3] demonstrated an association between older age and insufficiently treated OSA which is consistent with our findings. However, the French study excluded patients with mild OSA in contrast to our study population which included the entire spectrum of OSA severity. The second study excluded patients with high leak rates on their compliance data. Similar to our study, both studies used device generated AHI, however their study populations were not specifically limited to patients using the auto-adjusting CPAP delivery mode.

The insufficiently treated group also had lower body mass indices compared to the group with optimal AHI. The influence of age and BMI in determining responsiveness to APAP may be indicative of the previously reported heterogeneity of OSA [9] and may play an important role in targeted OSA therapy. Older patients and patients with lower BMIs may have OSA endotypes that may not respond as well to the current APAP algorithms and likely need

closer follow up after initiation of APAP or may benefit from alternative modes of PAP delivery or APAP algorithms. For instance, detection of vibrations from snoring is one of the signals utilized in some APAP based algorithms [10] and patients with lower BMI typically snore less. Therefore, one possibility is that the APAP algorithms may be less likely to detect respiratory events associated with less snoring. Furthermore, younger age, female sex and higher BMI have been associated with shorter duration of sleep disordered breathing events [11]. It is therefore possible that older patients and those with lower BMI need a more sustained increase in positive airway pressure delivery during respiratory events than that which is currently provided with current APAP algorithms. Older patients have been described as having an OSA endotype in which upper airway collapsibility plays a bigger role [12] and the variation in pressure delivery by APAP may leave more room for upper airway collapse when compared to the fixed pressure mode in these patients.

Polysomnographic data from the insufficiently treated group also revealed slightly higher central apnea indices on their baseline studies. Although this observation is consistent with prior findings [8] [13], the difference we observed in central apnea indices is unlikely to be clinically relevant or useful.

Analysis of APAP compliance data in our patients with insufficiently treated OSA revealed that they had higher peak average pressure requirements and longer mask leak durations, even after adjusting leak time for total nightly usage and 90th percentile pressure. Higher peak pressures have not typically been associated with higher residual AHI in prior

studies although one study reported that patients with CPAP pressure requirements of > 10 cm [3] had a higher residual AHI.

We found that greater air leak was associated with a higher likelihood of ineffective treatment. Prior data examining the contribution of leaks to higher residual AHI were attributed to the use of oronasal masks. These studies found oronasal masks were associated with higher leaks when compared to nasal masks [14] and nasal pillows [15]. While we found an association between higher residual AHI on APAP with increased leak, we did not find an association with mask type.

Similar to findings in prior studies [3] [13], we also found that the insufficiently treated group, not surprisingly, were less compliant with PAP therapy. One possibility is that low nightly usage hours can skew the AHI calculation due to small denominator values, similar to what is observed with split night studies [16]. Another possibility is that the presumed lack of clinical resolution of OSA symptoms related to a significant residual AHI precluded continued patient compliance with APAP. For instance, data from the SAVE trial found improvement in sleepiness, which is a common symptom of OSA, to be a predictor of compliance with CPAP therapy [17].

We found that 40.2% of our cohort were non-compliant. This is in accordance with prior studies which utilized the same compliance criteria and reported non-compliance rates of 37% [18] and 35.5% [19] respectively. Generally, reported CPAP non-adherence rates have been

highly variable, ranging from 29 to 83% [20]. Data on factors predicting adherence are also inconsistent [21]. While there were very few demographic, anthropometric or clinical differences between non-compliant and compliant patients, we found that younger patients and females were less likely to be compliant. It has been well documented that younger age is associated with worse adherence [22] and increasing age with improved adherence [23] [24]. One prior study reported that older males with more severe OSA were more likely to be compliant [25]. While several studies have reproduced the association between CPAP adherence and OSA severity [26], we did not observe increased adherence to therapy with increasing severity of OSA. This may have been because of the preponderance of severe OSA (>70%) in our cohort.

Non-compliance was also associated with longer leak durations. This finding has been documented in a prior study [27]. Another study documented poor adherence to APAP associated with higher leak volume adjusted for pressure delivery [28]. However prior data exploring the effects of mask leaks on CPAP compliance have been inconsistent. One study looking at the effects of types of CPAP interface on adherence documented that even though oronasal masks were associated with higher mask leaks, the adherence rates between different mask interfaces were not significantly different [14]. Another study observed that mask related side effects, of which mask leak was a common complaint, had a negative impact on adherence with PAP [22]. Clinical experience suggests that mask leaks may be disruptive to both patients' and bedpartners' sleep thus contributing to PAP intolerance and partner/spousal discord. Spousal involvement has been shown to play a positive role in CPAP compliance [29] and hence

spousal discord would be counterproductive. Furthermore, CPAP leaks are more likely to occur at higher CPAP pressure levels [30] which may lead to pressure discomfort and result in poor CPAP tolerance. Nevertheless, we did not find an association between CPAP pressure requirements and compliance.

We acknowledge that a major limitation of our study was that it was retrospective, non-randomized and we had > 50% missing data on mask types which may have resulted in a type 2 error. Despite the aforementioned limitations, our study examined important predictors of OSA treatment outcomes in a large cohort of patients using the increasingly popular auto-adjusting mode of CPAP delivery.

In conclusion, we found several demographic, anthropometric and clinical characteristics associated with worse APAP effectiveness and compliance. These observations have potential implications in the care of patients prescribed APAP. Patients with lower BMI and central apneas at baseline may benefit from early monitoring of their PAP data and treatment adjustments performed either remotely or at early follow up visits to ensure adequate control of OSA. Younger patients may require closer follow up as well. Early targeted behavioral and clinical interventions to improve compliance may be indicated particularly in this group of patients who are at risk of long-term cardiovascular consequences of untreated OSA. Finally, the detrimental effects of large mask leaks appear to be a commonality impacting both treatment effectiveness and adherence and thus affecting APAP treatment outcomes. Timely and ongoing interventions to minimize mask leaks may thus have a vital role to play in

improving APAP treatment outcomes in OSA. Clinical interventions which focus on careful mask fitting and enhanced training practices on proper mask application techniques during PAP delivery will likely be beneficial. Creating systems to flag and track patients with subjective leak complaints and/or significant leaks on PAP data for early follow up and re-fitting by respiratory technologists may help to address leaks early enough to reduce APAP therapy dropout rates.

Abbreviations

CPAP – Continuous Positive Airway Pressure

APAP – Auto-titrating Positive Airway Pressure

OSA – Obstructive Sleep Apnea

AHI- Apnea Hypopnea Index

RAHI – Residual AHI

BAHI – Baseline AHI

References

1. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG (2019) Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med* 15(02).
<https://doi.org/10.5664/jcsm.7640>
2. Nadal N, de Batlle J, Barbé F, Marsal JR, Sánchez-de-la-Torre A, Tarraubella N, Lavega M, Sánchez-de-la-Torre M (2018) Predictors of CPAP compliance in different clinical settings: primary care versus sleep unit. *Sleep Breath* 22(1).
<https://doi.org/10.1007/s11325-017-1549-7>
3. Bailly S, Daabek N, Jullian-Desayes I, Joyeux-Faure M, Sapène M, Grillet Y, Borel JC, Tamisier R, Pépin JL (2020) Partial failure of CPAP treatment for sleep apnoea: Analysis of the French national sleep database. *Respirology* 25(1).
<https://doi.org/10.1111/resp.13650>
4. Stammnitz A, Jerrentrup A, Penzel T, Peter JH, Vogelmeier C, Becker HF (2004) Automatic CPAP titration with different self-setting devices in patients with obstructive sleep apnoea. *Eur Respir J* 24(2). <https://doi.org/10.1183/09031936.04.00074304>
5. Berry RB, Parish JM, Hartse KM (2002). The use of auto-titrating continuous positive airway pressure for treatment of adult obstructive sleep apnea. An American Academy of Sleep Medicine review. *Sleep* 25(2).
6. Fashanu OS, Budhiraja R, Batool-Anwar S, Quan SF (2021) Titration studies overestimate continuous positive airway pressure requirements in uncomplicated obstructive sleep apnea. *J Clin Sleep Med*. <https://doi.org/10.5664/jcsm.9316>
7. Schwab RJ, Badr SM, Epstein LJ, Gay PC, Gozal D, Kohler M, Lévy P, Malhotra A, Phillips BA, Rosen, IM, Strohl KP, Strollo PJ, Weaver EM, Weaver TE & ATS Subcommittee on CPAP Adherence Tracking Systems (2013) An official American Thoracic Society statement: continuous positive airway pressure adherence tracking systems. The optimal monitoring strategies and outcome measures in adults. *Am J Respir Crit Care Med* 188(5). <https://doi.org/10.1164/rccm.201307-1282ST>
8. Reiter J, Zleik B, Bazalakova M, Mehta P, Thomas RJ (2016) Residual Events during Use of CPAP: Prevalence, Predictors, and Detection Accuracy. *J Clin Sleep Med* 12(8).
<https://doi.org/10.5664/jcsm.6056>
9. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A (2013) Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. *Am J Respir Crit Care Med* 188(8). <https://doi.org/10.1164/rccm.201303-0448OC>
10. Hosselet JJ (1999) [Auto-CPAP in the titration and treatment of obstructive respiratory sleep disorders]. *Rev Mal Respir* 16(5).
11. Borker PV, Reid M, Sofer T, Butler MP, Azarbarzin A, Wang H, Wellman A, Sands SA, Redline S (2021) Non-REM Apnea and Hypopnea Duration Varies across Population Groups and Physiologic Traits. *Am J Respir Crit Care Med* 203(9).
<https://doi.org/10.1164/rccm.202005-1808OC>

12. Edwards BA, Wellman A, Sands SA, Owens RL, Eckert DJ, White DP, Malhotra A (2014) Obstructive sleep apnea in older adults is a distinctly different physiological phenotype. *Sleep* 37(7). <https://doi.org/10.5665/sleep.3844>
13. Mulgrew AT, Lawati NA, Ayas NT, Fox N, Hamilton P, Cortes L, Ryan CF (2010) Residual sleep apnea on polysomnography after 3 months of CPAP therapy: clinical implications, predictors and patterns. *Sleep Med* 11(2). <https://doi.org/10.1016/j.sleep.2009.05.017>
14. Rowland S, Aiyappan V, Hennessy C, Catcheside P, Chai-Coezter CL, McEvoy RD, Antic NA (2018) Comparing the Efficacy, Mask Leak, Patient Adherence, and Patient Preference of Three Different CPAP Interfaces to Treat Moderate-Severe Obstructive Sleep Apnea. *J Clin Sleep Med* 14(1). <https://doi.org/10.5664/jcsm.6892>
15. Ebben MR, Oyegbile T, Pollak CP (2012) The efficacy of three different mask styles on a PAP titration night. *Sleep Med* 13(6). <https://doi.org/10.1016/j.sleep.2012.02.004>
16. Rouse JK, Shirley SR, Holley AB, Mysliwiec V, Walter RJ (2019) Split-Night Polysomnography Overestimates Apnea-Hypopnea Index in High-Risk Professions. *Mil Med* 184(5–6). <https://doi.org/10.1093/milmed/usy317>
17. van Ryswyk E, Anderson CS, Antic NA, Barbe F, Bittencourt L, Freed R, Heeley E, Liu Z, Loffler KA, Lorenzi-Filho G, Luo Y, Margalef MJM, McEvoy RD, Mediano O, Mukherjee S, Ou Q, Woodman R, Zhang X, Chai-Coetzer CL (2019) Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnea and cardiovascular disease. *Sleep* 42(10). <https://doi.org/10.1093/sleep/zsz152>
18. Lin HS, Prasad AS, Pan CJG, Rowley JA (2007) Factors associated with noncompliance to treatment with positive airway pressure. *Arch Otolaryngol Head Neck Surg* 133(1). <https://doi.org/10.1001/archotol.133.1.69>
19. Salepci B, Caglayan B, Kiral N, Parmaksiz ET, Comert SS, Sarac G, Fidan A, Gungor GA (2013) CPAP adherence of patients with obstructive sleep apnea. *Respir Care* 58(9). <https://doi.org/10.4187/respcare.02139>
20. Weaver TE, Grunstein RR (2008) Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. *Proc Am Thorac Soc* 5(2). <https://doi.org/10.1513/pats.200708-119MG>
21. Mehrtash M, Bakker JP, Ayas N (2019) Predictors of Continuous Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea. *Lung* 197(2). <https://doi.org/10.1007/s00408-018-00193-1>
22. Rotty MC, Suehs CM, Mallet JP, Martinez C, Borel JC, Rabec C, Bertelli F, Bourdin A, Molinari N, Jaffuel D (2021) Mask side-effects in long-term CPAP-patients impact adherence and sleepiness: the InterfaceVent real-life study. *Respir Res* 22(1). <https://doi.org/10.1186/s12931-021-01618-x>
23. May AM, Gharibeh T, Wang L, Hurley A, Walia H, Strohl KP, Mehra R (2018) CPAP Adherence Predictors in a Randomized Trial of Moderate-to-Severe OSA Enriched With Women and Minorities. *Chest* 154(3). <https://doi.org/10.1016/j.chest.2018.04.010>
24. Sabil A, le Vaillant M, Stitt C, Goupil F, Pigeanne T, Leclair-Visonneau L, Masson P, Bizieux-Thaminy A, Humeau MP, Meslier N, Gagnadoux F (2021) A CPAP data-based algorithm for automatic early prediction of therapy adherence. *Sleep Breath* 25(2). <https://doi.org/10.1007/s11325-020-02186-y>

25. Somers ML, Peterson E, Sharma S, Yaremchuk K (2011) Continuous positive airway pressure adherence for obstructive sleep apnea. *ISRN Otolaryngol*.
<https://doi.org/10.5402/2011/943586>
26. Campos-Rodriguez F, Martinez-Alonso M, Sanchez-de-la-Torre M, Barbe F & Spanish Sleep Network (2016) Long-term adherence to continuous positive airway pressure therapy in non-sleepy sleep apnea patients. *Sleep Med* 17.
<https://doi.org/10.1016/j.sleep.2015.07.038>
27. Sopkova Z, Dorkova Z, Tkacova R (2009) Predictors of compliance with continuous positive airway pressure treatment in patients with obstructive sleep apnea and metabolic syndrome. *Wien Klin Wochenschr* 121(11–12).
<https://doi.org/10.1007/s00508-009-1181-z>
28. Valentin A, Subramanian S, Quan SF, Berry RB, Parthasarathy S (2011) Air leak is associated with poor adherence to autoPAP therapy. *Sleep* 34(6).
<https://doi.org/10.5665/SLEEP.1054>
29. Batool-Anwar S, Baldwin CM, Fass S, Quan SF (2017) ROLE OF SPOUSAL INVOLVEMENT IN CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) ADHERENCE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA (OSA). *Southwest J Pulm Crit Care* 14(5).
<https://doi.org/10.13175/swjpcc034-17>
30. Lebrete M, Arnol N, Martinot JB, Lambert L, Tamisier R, Pepin JL, Borel JC (2018) Determinants of Unintentional Leaks During CPAP Treatment in OSA. *Chest* 153(4).
<https://doi.org/10.1016/j.chest.2017.08.017>

Table 1

Baseline Characteristics of study participants

	n = 172
Age (years)	63.4 ± 13.4
Gender (male) (%)	54.0
Race (non-Hispanic white) (%)	65.1
BMI (kg/m ²)	35.7 ± 8.6
Hypertension (%)	63.4
Congestive Heart Failure (%)	7.6
Atrial Fibrillation (%)	9.3
Cerebrovascular Accident (%)	5.8
Diabetes Mellitus (%)	25.0
Coronary Artery Disease (%)	14.0
Depression (%)	30.2
Regular BZD use (%)	7.6
Baseline AHI (events/hour)	51.4 ± 30.5
Snoring severity (severe)(%)	62.4
Apnea Index (events/hour)	20.9 ± 26.7
Obs Apnea Index (events/hour)	18.4 ± 24.8
Hypopnea Index (events/hour)	31.1 ± 18.8
Central Apnea Index (events/hour)	1.7± 3.9
Oxygen nadir (%)	78.6 ± 9.1

Table 2

APAP Effectiveness and Compliance Data

Residual AHI on PAP (events/hour)	5.4 ± 4.42
Residual AHI ≥ 5 on PAP (n, %)	65, 37.8
Mask Type (nasal)(%)	57.4%
Leak Duration (min/day)	13.9 ± 27.7
Leak Duration/Total nightly usage (min/hr)	6.7 ± 27.3
Leak Duration/90th percentile pressure (min/cmH2O)	0.7 ± 2.7
Percentage 4-hour usage per night	69.1 ± 30.5
<70% 4-hour usage/night (n, %)	69, 40.2
Mean Pressure (cmH2O)	8.8 ± 2.3
Peak Avg Pressure (cmH2O)	10.7 ± 2.6
90 th Percentile Pressure (cmH2O)	10.6 ± 2.5
Clinic Follow-up period (mon)	5.5 ± 3.6

Table 3

Comparison of groups based on achieving effective AHI (< 5 /h) on APAP

	RAHI < 5	RAHI ≥ 5	
Age (years)	60.4 ± 13.1	68.4 ± 12.5	<0.01
Gender (% men)	48.6	63.1	0.06
BMI (kg/m ²)	37.9 ± 9.1	31.9 ± 6.3	<0.01
HTN	58.9	70.8	0.11
DM	29	18.5	0.12
Depression	29.9	30.8	0.90
BAHI (events/hr)	52.1 ± 32.2	50.3 ± 27.6	0.71
Snoring Severity n = 133 (severe)	65.1	39.4	0.44
CAI (events/hr)	1.2 ± 3.6	2.5 ± 4.2	0.046
AI	19.7 ± 27.4	22.8 ± 25.8	0.47
AI/HI	1.8 ± 6.9	1.6 ± 3.5	0.87
Mask Type n = 68 (nasal)	61	51.9	0.46
Leak Duration (min/day) n = 162	6.6 ± 13.8	25.9 ± 38.8	<0.01
Leak Duration/total nightly usage (min/hour) n = 160	2.1± 6.2	14.1± 42.7	<0.01
Leak Duration /90th percentile pressure (min/cmH ₂ O) n = 160	0.2 ± 0.5	1.4 ± 4.3	<0.01
4 hour usage (%) n = 164	73.9 ± 27.4	61.2 ± 33.6	<0.01
Mean Pressure (cmH ₂ O) n = 164	8.6 ± 2.3	9.1 ± 2.4	0.23

Peak Avg Pressure (cmH2O) n=161	10.3 ± 2.4	11.4 ± 2.6	0.013
90 th Percentile P (cmH2O) n = 162	10.3 ± 2.4	11 ± 2.6	0.07

Table 4

Comparison of groups based on APAP Treatment Compliance

	Compliant (n = 98)	Non-compliant (n = 66)	p-value
Age (years)	65.5 ± 13.2	61.1 ± 12.6	0.03
Gender (men) %	60.2	43.9	0.04
BMI (kg/m ²)	35.3 ± 7.9	36.4 ± 9.6	0.41
HTN	65.3	59.1	0.42
DM	22.4	27.3	0.48
Depression	24.5	37.9	0.06
Baseline AHI (events/hour)	53.9 ± 29.2	48.0 ± 33.0	0.24
Snoring Severity n = 128 (severe)	62	63.2	0.86
Mask Type n = 63 (nasal)	53.1	58.1	0.69
Mean Pressure(cmH ₂ O)	8.8 ± 2.4	8.8 ± 2.3	0.81
Peak Avg Pressure (cmH ₂ O)	10.8 ± 2.6	10.7 ± 2.5	0.91
90 th Percentile Pressure (cmH ₂ O)	10.6 ± 2.6	10.4 ± 2.5	0.61
Leak Duration (min/day)	12.2 ± 24.7	16.4 ± 31.8	0.35
Leak Duration/Total nightly usage (min/hr)	1.8 ± 3.5	13.9 ± 42.1	0.006
Leak Duration /90th Percentile pressure (min/cmH ₂ O)	0.2 ± 0.3	1.4 ± 4.2	0.005

Residual AHI on APAP	5.2 ± 4.0	6.1 ± 5.1	0.21
Follow up Period	5.5 ± 3.7	5.6 ± 3.5	0.83

Table 5

Comparison of Groups based on Outcomes on APAP

	Optimally treated (n= 65)	Not optimally treated (n=29)	p-value
BMI	37.5 ± 8.3	33.2 ± 7.8	0.02
Leak Duration (min/day)	7.3 ± 16.5	30.7 ± 44.1	<0.01
Leak Duration/Total nightly usage (min/hr)	1.1 ± 2.2	26.9 ± 60.8	<0.01
Leak Duration /90th Percentile pressure (min/cmH ₂ O)	0.1 ± 0.2	2.75 ± 6.1	<0.01
Nightly usage (hr)	6.9 ± 1.7	2.5 ± 1.4	<0.01